IN2014MN02114A - - Google Patents
Info
- Publication number
- IN2014MN02114A IN2014MN02114A IN2114MUN2014A IN2014MN02114A IN 2014MN02114 A IN2014MN02114 A IN 2014MN02114A IN 2114MUN2014 A IN2114MUN2014 A IN 2114MUN2014A IN 2014MN02114 A IN2014MN02114 A IN 2014MN02114A
- Authority
- IN
- India
- Prior art keywords
- akt3
- emt
- epithelial
- occurrence
- subject
- Prior art date
Links
- 230000007705 epithelial mesenchymal transition Effects 0.000 abstract 4
- 101150051155 Akt3 gene Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641512P | 2012-05-02 | 2012-05-02 | |
| GB201207722A GB201207722D0 (en) | 2012-05-02 | 2012-05-02 | Method |
| PCT/IB2013/053488 WO2013164788A2 (en) | 2012-05-02 | 2013-05-02 | Method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02114A true IN2014MN02114A (OSRAM) | 2015-09-04 |
Family
ID=46330714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2114MUN2014 IN2014MN02114A (OSRAM) | 2012-05-02 | 2013-05-02 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10317405B2 (OSRAM) |
| EP (1) | EP2845004A2 (OSRAM) |
| JP (2) | JP2015525060A (OSRAM) |
| KR (1) | KR102179389B1 (OSRAM) |
| CN (1) | CN104335046B (OSRAM) |
| AU (1) | AU2013255456B2 (OSRAM) |
| BR (1) | BR112014027219A2 (OSRAM) |
| CA (1) | CA2871352A1 (OSRAM) |
| EA (1) | EA201401201A1 (OSRAM) |
| GB (1) | GB201207722D0 (OSRAM) |
| IN (1) | IN2014MN02114A (OSRAM) |
| SG (1) | SG11201407032WA (OSRAM) |
| WO (1) | WO2013164788A2 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106460067A (zh) * | 2014-07-14 | 2017-02-22 | 豪夫迈·罗氏有限公司 | 诊断方法和用于治疗成胶质细胞瘤的组合物 |
| GB201420239D0 (en) * | 2014-11-14 | 2014-12-31 | Bergenbio As | Biomarker |
| GB201512133D0 (en) | 2015-07-10 | 2015-08-19 | Bergenbio As | Biomarkers |
| KR101941054B1 (ko) * | 2016-07-20 | 2019-01-23 | 연세대학교 산학협력단 | 암 예후 예측을 위한 조성물 및 이를 포함하는 키트 |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| KR102080384B1 (ko) * | 2018-02-28 | 2020-02-21 | 주식회사 마크로젠 | 암줄기세포 특이적 바이오마커 |
| US20220008358A1 (en) * | 2018-11-12 | 2022-01-13 | Agency For Science, Technology And Research | Methods for manipulating cell state transitions in cancer |
| JP2023525758A (ja) * | 2020-05-08 | 2023-06-19 | ジョージアミューン・インコーポレイテッド | Ａｋｔ３モジュレーターおよびその使用方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6809194B1 (en) | 2000-05-10 | 2004-10-26 | Chiron Corporation | Akt3 inhibitors |
| US20040121413A1 (en) | 2002-12-20 | 2004-06-24 | Aebersold Rudolf H. | Androgen-regulated genes and uses for diagnosis, prognosis and treatment of prostate neoplastic conditions |
| WO2004086038A2 (en) | 2003-03-28 | 2004-10-07 | Institut Curie | A method for screening compounds having the capacity to control tumor cell invasion or metastasis using constitutively active akt |
| ATE446752T1 (de) * | 2003-04-24 | 2009-11-15 | Merck & Co Inc | Hemmer der akt aktivität |
| WO2008042867A2 (en) * | 2006-09-29 | 2008-04-10 | Emiliem Inc. | Modulators of multiple kinases |
| WO2008098139A2 (en) | 2007-02-07 | 2008-08-14 | The Regents Of The University Of Colorado | Axl tyrosine kinase inhibitors and methods of making and using the same |
| CN101743007B (zh) * | 2007-07-12 | 2015-04-08 | 南佛罗里达大学 | 具有抗肿瘤活性的akt/pkb抑制剂 |
| AU2008289442A1 (en) * | 2007-08-21 | 2009-02-26 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
| EP2235179B1 (en) | 2007-12-24 | 2017-11-15 | BerGenBio ASA | Methods for creating and identifying functional rna interference elements |
| US8067178B2 (en) | 2008-03-14 | 2011-11-29 | Genomic Health, Inc. | Gene expression markers for prediction of patient response to chemotherapy |
| SG172997A1 (en) | 2009-01-16 | 2011-08-29 | Rigel Pharmaceuticals Inc | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
| EP2409156A4 (en) | 2009-02-06 | 2013-07-17 | H Lee Moffitt Cancer Ct & Res | PHOSPHORYLATION OF ACT-TYROSINE 176 AS CANCER BIOMARKER |
| WO2010103388A2 (en) | 2009-03-13 | 2010-09-16 | Bergen Teinologioverforing As | Method |
| WO2010115119A2 (en) | 2009-04-02 | 2010-10-07 | Tufts Medical Center, Inc. | Compositions and methods for diagnosis and prognosis of cancer and progression, and for screening anti-cancer agents |
| WO2011050351A2 (en) | 2009-10-23 | 2011-04-28 | The Translational Genomics Research Institute | Methods and kits used in identifying glioblastoma |
| US20120213801A1 (en) | 2009-10-30 | 2012-08-23 | Ekaterina Gresko | Phosphorylated Twist1 and cancer |
| MX338883B (es) | 2010-07-27 | 2016-05-04 | Genomic Health Inc | Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata. |
| WO2012032143A1 (en) * | 2010-09-10 | 2012-03-15 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Phosphorylated twist1 and metastasis |
| WO2012061510A2 (en) * | 2010-11-03 | 2012-05-10 | Merck Sharp & Dohme Corp. | Methods of predicting cancer cell response to therapeutic agents |
-
2012
- 2012-05-02 GB GB201207722A patent/GB201207722D0/en not_active Ceased
-
2013
- 2013-05-02 EA EA201401201A patent/EA201401201A1/ru unknown
- 2013-05-02 AU AU2013255456A patent/AU2013255456B2/en not_active Ceased
- 2013-05-02 WO PCT/IB2013/053488 patent/WO2013164788A2/en not_active Ceased
- 2013-05-02 KR KR1020147032804A patent/KR102179389B1/ko not_active Expired - Fee Related
- 2013-05-02 BR BR112014027219A patent/BR112014027219A2/pt not_active Application Discontinuation
- 2013-05-02 SG SG11201407032WA patent/SG11201407032WA/en unknown
- 2013-05-02 CA CA2871352A patent/CA2871352A1/en not_active Abandoned
- 2013-05-02 JP JP2015509554A patent/JP2015525060A/ja active Pending
- 2013-05-02 US US14/398,572 patent/US10317405B2/en not_active Expired - Fee Related
- 2013-05-02 CN CN201380023276.5A patent/CN104335046B/zh not_active Expired - Fee Related
- 2013-05-02 EP EP13728839.5A patent/EP2845004A2/en not_active Withdrawn
- 2013-05-02 IN IN2114MUN2014 patent/IN2014MN02114A/en unknown
-
2017
- 2017-03-17 JP JP2017052865A patent/JP6738755B2/ja not_active Expired - Fee Related
-
2019
- 2019-05-10 US US16/408,816 patent/US20200072839A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA201401201A1 (ru) | 2015-02-27 |
| AU2013255456B2 (en) | 2018-07-26 |
| CA2871352A1 (en) | 2013-11-07 |
| JP2017136077A (ja) | 2017-08-10 |
| GB201207722D0 (en) | 2012-06-13 |
| US20150119475A1 (en) | 2015-04-30 |
| EP2845004A2 (en) | 2015-03-11 |
| US10317405B2 (en) | 2019-06-11 |
| US20200072839A1 (en) | 2020-03-05 |
| CN104335046A (zh) | 2015-02-04 |
| WO2013164788A3 (en) | 2014-01-23 |
| JP2015525060A (ja) | 2015-09-03 |
| WO2013164788A2 (en) | 2013-11-07 |
| SG11201407032WA (en) | 2014-11-27 |
| BR112014027219A2 (pt) | 2017-06-27 |
| CN104335046B (zh) | 2019-10-11 |
| JP6738755B2 (ja) | 2020-08-12 |
| KR102179389B1 (ko) | 2020-11-18 |
| AU2013255456A1 (en) | 2014-11-13 |
| KR20150016518A (ko) | 2015-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02114A (OSRAM) | ||
| EP3065772A4 (en) | Combinations of checkpoint inhibitors and therapeutics to treat cancer | |
| TWD159653S (zh) | 個人電腦（一） | |
| TWD165363S (zh) | 錶殼 | |
| BR112013010099A2 (pt) | boronatos como inibidores de arginase | |
| UA118248C2 (uk) | Інгібітори глюкозилцерамідсинтази | |
| TWD162033S (zh) | 手錶 | |
| UA118658C2 (uk) | СПОСІБ ДІАГНОСТИКИ ПРОГНОЗУ ВІДПОВІДІ НА ІНГІБІТОР TNFα | |
| WO2013186639A3 (en) | Methylation biomarkers for breast cancer | |
| MX367255B (es) | Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b). | |
| PH12014502382A1 (en) | Anti-robo4-antibody | |
| UA112760C2 (uk) | Теобромін у комбінації з гвайфенезином для лікування кашлю | |
| MX345702B (es) | Aparato y metodos de inversion de datos. | |
| EA201492152A1 (ru) | Налмефен для уменьшения потребления алкоголя у конкретных целевых популяций | |
| TWD172356S (zh) | 錶殼 | |
| TWD158435S (zh) | 個人電腦（三） | |
| WO2012145399A3 (en) | Methods of diagnosing cancer in a patient | |
| TWD158434S (zh) | 個人電腦（二） | |
| NZ631749A (en) | Methods of treating cancer using angiogenin or an angiogenin agonist | |
| MX2013005759A (es) | Metodos para detectar bajo grado de inflamacion. | |
| NZ703905A (en) | Method of treating multiple sclerosis by using narrow band uvb | |
| IN2014MN01871A (OSRAM) | ||
| PH12016500541A1 (en) | Use of odiparcil in the treatment of a mucopolysaccharidosis | |
| GB201318729D0 (en) | Indicator molecules for use in detecting enzyme cleavage activity | |
| UA58801U (ru) | Способ экспрессного тест-определения нитрит-ионов |